OGC
ACRS icon

One68 Global Capital’s Aclaris Therapeutics ACRS Stock Holding History

One68 Global Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$157K Buy
+24,328
New +$103K 0.32% 60

Other funds holding ACRS

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

One68 Global Capital's ACRS Position: Q4 2020 in Review

One68 Global Capital opened a new position in Aclaris Therapeutics (ACRS) in Q4 2020: 24,328 shares worth $157K. The stake represents 0.32% of the portfolio and ranks #60 among its holdings.

82 funds tracked by Wall St. Rank hold ACRS as of Q4 2020.

  • One68 Global Capital held 24,328 shares of Aclaris Therapeutics worth $157K as of Q4 2020.
  • Aclaris Therapeutics was a new One68 Global Capital position in Q4 2020.
  • Aclaris Therapeutics made up 0.32% of One68 Global Capital's portfolio in Q4 2020, its #60 holding.
  • 82 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2020.

Based on One68 Global Capital's 13F filing for Q4 2020, filed 16 Feb 2021.